Neurodegenerative Diseases Therapeutics

Neurodegenerative Diseases Therapeutics

Global Neurodegenerative Diseases Therapeutics Market to Reach US$71.7 Billion by 2030

The global market for Neurodegenerative Diseases Therapeutics estimated at US$47.2 Billion in the year 2023, is expected to reach US$71.7 Billion by 2030, growing at a CAGR of 6.2% over the analysis period 2023-2030. Immunomodulators, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$30.0 Billion by the end of the analysis period. Growth in the Dopamine Agonists segment is estimated at 5.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$12.9 Billion While China is Forecast to Grow at 10.0% CAGR

The Neurodegenerative Diseases Therapeutics market in the U.S. is estimated at US$12.9 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$15.4 Billion by the year 2030 trailing a CAGR of 10.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 6.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

Global Neurodegenerative Diseases Therapeutics Market - Key Drivers and Trends Summarized

 

Neurodegenerative diseases therapeutics encompass a broad array of treatments aimed at managing and potentially altering the course of diseases characterized by progressive nervous system dysfunction. These diseases include Alzheimer`s, Parkinson`s, Huntington`s, and amyotrophic lateral sclerosis (ALS), among others. The primary focus of these therapeutics is to alleviate symptoms, improve quality of life, and, in some cases, slow disease progression. Treatments range from pharmacological interventions, such as cholinesterase inhibitors and dopamine agonists, to advanced approaches like gene therapy and neuroprotective agents.

Over the past decade, the field of neurodegenerative disease therapeutics has witnessed remarkable advancements, propelled by a deeper understanding of disease mechanisms and technological innovations. Traditional pharmacological treatments have been supplemented by novel approaches targeting the underlying pathology of these diseases. For instance, monoclonal antibodies designed to clear amyloid-beta plaques have shown promise in Alzheimer`s disease, while gene therapies are being explored for their potential to correct genetic mutations in conditions like Huntington`s disease. Additionally, the use of biomarkers for early diagnosis and personalized medicine approaches are becoming increasingly prevalent, allowing for more tailored and effective treatment strategies. Clinical trials and research efforts continue to expand, providing a pipeline of potential new therapies that could transform the management of neurodegenerative diseases.

The growth in the neurodegenerative diseases therapeutics market is driven by several factors, including technological advancements, increasing prevalence of neurodegenerative disorders, and heightened investment in research and development. Innovations in biotechnology and molecular biology have paved the way for cutting-edge treatments such as CRISPR-based gene editing and stem cell therapies, which hold the promise of addressing the root causes of these diseases. The aging global population is contributing to a higher incidence of neurodegenerative conditions, thereby increasing the demand for effective treatments. Furthermore, substantial investments from pharmaceutical companies and government agencies are fueling the development of new therapeutics. Collaborative efforts between academia, industry, and regulatory bodies are accelerating the pace of discovery and approval of new treatments. These factors, combined with a growing understanding of disease mechanisms and the advent of precision medicine, are driving the robust expansion of the neurodegenerative diseases therapeutics market, offering hope for improved outcomes for patients worldwide.

Select Competitors (Total 86 Featured) -

• AbbVie, Inc.
• Alector, Inc.
• AstraZeneca PLC
• Biohaven, Ltd.
• Bristol-Myers Squibb Company
• Coya Therapeutics
• Denali Therapeutics, Inc.
• Eli Lilly and Company
• Genentech, Inc.
• H. Lundbeck A/S
• Ionis Pharmaceuticals, Inc.
• Les Laboratoires Servier
• MD Biosciences, Inc.
• Ono Pharmaceutical Co., Ltd.
• Prothena Corporation PLC;

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.